Drugs / Intravenous Immunoglobulins, Human
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT06041451 | Jan 2013 → Dec 2022 | Guillain-Barre syndrome | First Affiliated Hospital of Wenzhou Medical University | Unknown | No outcome recorded |
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT03749096 Comparator | Dec 2018 → Apr 2019 | classic stiff person syndrome | Mayo Clinic | Withdrawn | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT06697431 Comparator | Apr 2025 → Apr 2026 overdue | Kawasaki disease | Meyer Children's Hospital IRCCS | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Intravenous Immunoglobulins, Human | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03749096 ↗ |
| Known as | intravenous immunoglobulin | “patients were treated with intravenous immunoglobulin(30g ivgtt qd) for 5 days” NCT06041451 ↗ |
| Modality | Protein / enzyme biologic | “Immunoglobulins are fractionated blood products made from pooled human plasma.” NCT03749096 ↗ |
| Route | Intravenous | “IVIg/placebo (saline) treatments will be administered on 2 consecutive days in week 1, week 5, week 9 in all patients.” NCT03749096 ↗ |